医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pacific Prime Launches the State of Health Insurance Report 2020-2021

2021年08月31日 AM11:00
このエントリーをはてなブックマークに追加


 

HONG KONG

Pacific Prime, a global health insurance brokerage and employee benefits specialist, has released the fourth edition of their annual State of Health Insurance Report. Taking a deep dive into the International Private Medical Insurance (IPMI) space, the report gathers insight from key industry leaders such as Julian Mengual, CEO – South East Asia & Regional Health Solutions at Cigna, and Andrew Merrilees, General Manager at Bupa Hong Kong, to act as a one-stop resource for individuals and corporates alike. In particular, the report explores the implications for HR teams and their employee benefits offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005234/en/

Pacific Prime launches the State of Health Insurance Report 2020-2021 (Graphic: Business Wire)

Pacific Prime launches the State of Health Insurance Report 2020-2021 (Graphic: Business Wire)

With the world still reeling from the impacts of the COVID-19 pandemic, the State of Health Insurance Report 2020-2021 explores delayed medical treatments, rising mental health concerns, and tightening budgets, amongst others. It also uncovers technological innovation in the healthcare and health insurance space to tackle some of the challenges posed by the pandemic. Against the backdrop of these overarching trends, the report combines insight from their in-house employee benefits experts and insurance partners like Cigna and Bupa Hong Kong to give readers a nuanced understanding of where the sector is headed.

Neil Raymond, Founder and CEO at Pacific Prime, said: “I’m very excited to say that Pacific Prime has released yet another fantastic insurance resource. During these unprecedented times, the State of Health Insurance Report offers much-needed clarity on the ever-changing health insurance landscape.”

To facilitate digestible reading, the report is divided into two main sections:

  • Changes and trends shaping the global health insurance industry:
    • Insurers and clients continue to cope with the financial impact of COVID-19

    • Major healthcare trends and challenges

    • Impact of COVID-19 on the insurance industry

    • Changing consumer needs and expectations for insurtech, including the ability to personalize their benefits selections via flex benefits

  • Regional health insurance trends across five continents, including in-depth analysis for the locations where Pacific Prime has a presence in:
    • Hong Kong, China, Singapore, Thailand, the UAE, the UK, Mexico, and the USA.

Download the free report for a complete look at the findings.

About Pacific Prime

Established in 2000, Pacific Prime is a technology-driven, global health insurance brokerage and employee benefits specialist. Operating out of its headquarters in Hong Kong and 12 regional offices across key locations in Asia, the Middle East, Europe, and the Americas, Pacific Prime specializes in matching individuals, families, groups, and corporates with the best insurance solution for their needs and budgets.

To learn more about Pacific Prime, contact their insurance advisors or visit: https://www.pacificprime.com/corporate/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005234/en/

CONTACT

Stephen Ho

Marketing Director

Pacific Prime and Kwiksure

+852 3589 0508

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™